Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains.

Literature DB >> 11302834

Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains.

S Valdezate¹, A Vindel, E Loza, F Baquero, R Cantón.

Abstract

Susceptibility to 41 antimicrobials was studied with 99 Stenotrophomonas maltophilia strains, and different pulsed-field gel electrophoresis profiles were identified among 130 prospectively collected isolates. Moxalactam, doxycycline, minocycline, and clinafloxacin displayed the highest activity (> or = 98% susceptibility). Ticarcillin resistance (75%) was reverted by clavulanate in 25% of strains. Trimethoprim-sulfamethoxazole resistance was 26.2% (> or = 4 [trimethoprim]/76 [sulfamethoxazole] microg/ml) and dropped to 11.1% when an 8/152-microg/ml breakpoint was applied based on its bimodal MIC distribution. Resistance was lower when unique strains were considered, because clonal organisms contribute to resistance.

Entities: Chemical Species

Mesh：

Substances：
Anti-Bacterial Agents

Year: 2001 PMID： 11302834 PMCID： PMC90512 DOI： 10.1128/AAC.45.5.1581-1584.2001

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

23 in total

1. Susceptibility of 100 strains of Stenotrophomonas maltophilia to three beta-lactams and five beta-lactam-beta-lactamase inhibitor combinations.

Authors: M Lecso-Bornet; E Bergogne-Bérézin
Journal: J Antimicrob Chemother Date: 1997-11 Impact factor: 5.790

Review 2. Macrolides for the treatment of Pseudomonas aeruginosa infections?

Authors: R A Howe; R C Spencer
Journal: J Antimicrob Chemother Date: 1997-08 Impact factor: 5.790

3. Multiple antibiotic resistance in Stenotrophomonas maltophilia.

Authors: A Alonso; J L Martínez
Journal: Antimicrob Agents Chemother Date: 1997-05 Impact factor: 5.191

4. Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia.

Authors: T R Walsh; A P MacGowan; P M Bennett
Journal: Antimicrob Agents Chemother Date: 1997-07 Impact factor: 5.191

Review 5. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors: F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal: J Clin Microbiol Date: 1995-09 Impact factor: 5.948

6. The barrier function of the outer membrane of Pseudomonas maltophilia in the diffusion of saccharides and beta-lactam antibiotics.

Authors: E Yamazaki; J Ishii; K Sato; T Nakae
Journal: FEMS Microbiol Lett Date: 1989-07-01 Impact factor: 2.742

7. Susceptibility testing of Stenotrophomonas maltophilia to carbapenems.

Authors: R A Howe; M P Wilson; T R Walsh; M R Millar
Journal: J Antimicrob Chemother Date: 1997-07 Impact factor: 5.790

8. In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity.

Authors: J L Muñoz Bellido; S Muñoz Criado; I García García; M A Alonso Manzanares; M N Gutiérrez Zufiaurre; J A García-Rodríguez
Journal: Antimicrob Agents Chemother Date: 1997-12 Impact factor: 5.191

9. In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods.

Authors: M Arpi; M A Victor; I Mortensen; A Gottschau; B Bruun
Journal: APMIS Date: 1996-02 Impact factor: 3.205

10. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998.

Authors: S Valdezate; A Vindel; L Maiz; F Baquero; H Escobar; R Cantón
Journal: Emerg Infect Dis Date: 2001 Jan-Feb Impact factor: 6.883

22 in total

1. In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole.

Authors: Evangelos J Giamarellos-Bourboulis; Lazaros Karnesis; Irene Galani; Helen Giamarellou
Journal: Antimicrob Agents Chemother Date: 2002-12 Impact factor: 5.191

2. Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates.

Authors: Raquel Barbolla; Mariana Catalano; Betina E Orman; Angela Famiglietti; Carlos Vay; Jorgelina Smayevsky; Daniela Centrón; Silvia A Piñeiro
Journal: Antimicrob Agents Chemother Date: 2004-02 Impact factor: 5.191

3. Multiple antimicrobial resistance of gram-negative bacteria from natural oligotrophic lakes under distinct anthropogenic influence in a tropical region.

Authors: D S Pontes; F A Pinheiro; C I Lima-Bittencourt; R L M Guedes; L Cursino; F Barbosa; F R Santos; E Chartone-Souza; A M A Nascimento
Journal: Microb Ecol Date: 2009-06-06 Impact factor: 4.552

Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains.

1. Susceptibility of 100 strains of Stenotrophomonas maltophilia to three beta-lactams and five beta-lactam-beta-lactamase inhibitor combinations.

Review 2. Macrolides for the treatment of Pseudomonas aeruginosa infections?

3. Multiple antibiotic resistance in Stenotrophomonas maltophilia.

4. Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia.

Review 5. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

6. The barrier function of the outer membrane of Pseudomonas maltophilia in the diffusion of saccharides and beta-lactam antibiotics.

7. Susceptibility testing of Stenotrophomonas maltophilia to carbapenems.

8. In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity.

9. In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods.

10. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998.

1. In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole.

2. Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates.

3. Multiple antimicrobial resistance of gram-negative bacteria from natural oligotrophic lakes under distinct anthropogenic influence in a tropical region.

4. Antibiotics resistance of Stenotrophomonas maltophilia strains isolated from various clinical specimens.

5. Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients.

6. Stenotrophomonas infection in a patient with glucose-6-phosphate dehydrogenase deficiency.

Review 7. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

8. A review of 11 years of Stenotrophomonas maltophilia blood isolates at a tertiary care institute in Canada.

9. Double-disk synergy test positivity in Stenotrophomonas maltophilia clinical strains.

10. High genetic diversity among Stenotrophomonas maltophilia strains despite their originating at a single hospital.